---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020588"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:07:17.073253+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenaya reports Q1 net loss $31.7M; cash $173.6M; TN-201 gets FDA Fast Track

## Summary
- Cash, equivalents and marketable securities $173.6M as of March 31, 2023; runway into H1 2025.
- Net loss $31.7M ($0.43/share); R&D expense $25.6M, G&A $8.1M for Q1 2023.
- TN-201 (gene therapy for HCM) received FDA Fast Track designation; Phase 1b to start Q3 2023.
- Phase 1 dosing of TN-301 (HDAC6 inhibitor for HFpEF) complete; data expected H2 2023.
- New Scientific Advisory Board members (Drs. Seidman, Marson) and Technical Advisory Board formed.

## SEC filing metadata
- accession: 0000950170-23-020588
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/0000950170-23-020588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/tnya-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020588
- JSON: https://secwatch.observer/filing/0000950170-23-020588.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020588.txt

## Key facts
- Earnings Releases
  Tenaya Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 10, 2023, Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/0000950170-23-020588-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.